# reload+after+2024-01-22 00:47:32.633527
address1§1065 East Hillsdale Boulevard
address2§Suite 100
city§Foster City
state§CA
zip§94404
country§United States
phone§650 525 5535
fax§650 275 4254
website§https://www.ternspharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
fullTimeEmployees§46
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Erin  Quirk M.D.', 'age': 52, 'title': 'President & Head of Research & Development', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 808160, 'exercisedValue': 0, 'unexercisedValue': 588290}, {'maxAge': 1, 'name': 'Mr. Seokho  Yoon Esq.', 'age': 45, 'title': 'COO, General Counsel & Secretary', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 712840, 'exercisedValue': 0, 'unexercisedValue': 249829}, {'maxAge': 1, 'name': 'Dr. Weidong  Zhong Ph.D.', 'age': 57, 'title': 'Co-Founder & Executive Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark Joseph Vignola', 'age': 45, 'title': 'CFO & Treasurer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 402150, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey R. Jasper Ph.D.', 'title': 'Senior VP & Head of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Diana  Chung', 'title': 'Senior VP & Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Emil T. Kuriakose M.D.', 'age': 43, 'title': 'Chief Medical Officer of Oncology', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.814
currency§USD
dateShortInterest§1702598400
forwardEps§-1.4
exchange§NMS
quoteType§EQUITY
shortName§Terns Pharmaceuticals, Inc.
longName§Terns Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1612535400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7e7e889b-1f93-38a3-8cbf-64bb942bfd16
gmtOffSetMilliseconds§-18000000
targetHighPrice§19.0
targetLowPrice§8.0
targetMeanPrice§14.29
targetMedianPrice§17.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§22.057
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
